Pentwater Capital Management LP 13D and 13G filings for Poseida Therapeutics, Inc.:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Shares have been adjusted for stock splits.
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-01-13 4:05 pm Sale | 2025-01-08 | 13D | Poseida Therapeutics, Inc. PSTX | Pentwater Capital Management LP | 0 0.000% | -8,625,000 (Position Closed) | Filing |
| 2024-11-27 7:01 pm Purchase | 2024-11-25 | 13D | Poseida Therapeutics, Inc. PSTX | Pentwater Capital Management LP | 8,625,000 8.800% | 3,657,773 (+73.64%) | Filing |
| 2022-04-25 4:30 pm Unchanged | 2022-04-22 | 13D | Poseida Therapeutics, Inc. PSTX | Pentwater Capital Management LP | 4,967,227 7.940% | 0 (Unchanged) | Filing |
| 2020-12-28 4:05 pm Purchase | 2020-12-16 | 13D | Poseida Therapeutics, Inc. PSTX | Pentwater Capital Management LP | 4,967,227 8.030% | 4,967,227 (New Position) | Filing |